Surufatinib plus chemotherapy before surgery for osteosarcoma
Part of Cancer clinical trials.
This Phase 2 trial studies whether surufatinib combined with chemotherapy given before surgery can shrink osteosarcoma and improve outcomes. It may help by attacking the tumor from more than one angle before the main treatment step.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must agree to the study and sign informed consent
- Aged 2 to 70 years with a primary bone tumor confirmed by pathology (cell/tissue testing)
- No prior anti-cancer treatment for this cancer (including chemo, immune therapy, targeted drugs, or surufatinib)
- Must have at least one measurable tumor area on scans
- Need generally good blood counts, liver and kidney function based on lab tests
- Must be able to take pills by mouth and not have serious bleeding risk or uncontrolled high blood pressure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug envafolimab to standard chemotherapy before surgery can help treat stage IIb osteosarcoma (a type of bone cancer) that hasn't spread. The goal is to see if this combination makes the tumor shrink more and improves outcomes.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This early-phase study tests whether adding losartan to sunitinib can help control osteosarcoma that has returned or keeps growing after at least one prior treatment. It may help by targeting the cancer’s growth signals and blood supply, but the goal at this stage is mainly to check safety and find workable dosing.
This early-phase study tests sulfatinib in children, teens, and young adults with high-grade osteosarcoma that has returned or does not respond to standard treatment. It may help shrink tumors or control the disease, and it also aims to find safe dosing.
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.